168 related articles for article (PubMed ID: 9845116)
1. Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI.
Maxwell RJ; Nielsen FU; Breidahl T; Stødkilde-Jørgensen H; Horsman MR
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):891-4. PubMed ID: 9845116
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.
Beauregard DA; Thelwall PE; Chaplin DJ; Hill SA; Adams GE; Brindle KM
Br J Cancer; 1998 Jun; 77(11):1761-7. PubMed ID: 9667644
[TBL] [Abstract][Full Text] [Related]
3. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
[TBL] [Abstract][Full Text] [Related]
4. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.
Thoeny HC; De Keyzer F; Chen F; Ni Y; Landuyt W; Verbeken EK; Bosmans H; Marchal G; Hermans R
Radiology; 2005 Mar; 234(3):756-64. PubMed ID: 15734932
[TBL] [Abstract][Full Text] [Related]
5. Cerebral metabolism in experimental hydrocephalus: an in vivo 1H and 31P magnetic resonance spectroscopy study.
Braun KP; van Eijsden P; Vandertop WP; de Graaf RA; Gooskens RH; Tulleken KA; Nicolay K
J Neurosurg; 1999 Oct; 91(4):660-8. PubMed ID: 10507389
[TBL] [Abstract][Full Text] [Related]
6. The potential of hyperpolarized
Iversen AB; Busk M; Bertelsen LB; Laustsen C; Munk OL; Nielsen T; Wittenborn TR; Bussink J; Lok J; Stødkilde-Jørgensen H; Horsman MR
Acta Oncol; 2017 Nov; 56(11):1626-1633. PubMed ID: 28840759
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effects of high dose irradiation on canine thigh muscle by follow-up magnetic resonance imaging and phosphorus-31 magnetic resonance spectroscopy.
Choe BY; Jee WH; Suh TS; Lee HK; Shinn KS
Invest Radiol; 1998 May; 33(5):300-7. PubMed ID: 9609489
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI.
Maxwell RJ; Wilson J; Prise VE; Vojnovic B; Rustin GJ; Lodge MA; Tozer GM
NMR Biomed; 2002 Apr; 15(2):89-98. PubMed ID: 11870904
[TBL] [Abstract][Full Text] [Related]
9. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors.
Horsman MR; Ehrnrooth E; Ladekarl M; Overgaard J
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):895-8. PubMed ID: 9845117
[TBL] [Abstract][Full Text] [Related]
10. Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy.
Nordsmark M; Maxwell RJ; Wood PJ; Stratford IJ; Adams GE; Overgaard J; Horsman MR
Br J Cancer Suppl; 1996 Jul; 27():S232-5. PubMed ID: 8763887
[TBL] [Abstract][Full Text] [Related]
11. The investigation of experimental brain tumours using 31P-MRS and 1H-MRI.
Hirakawa K; Naruse S; Higuchi T; Horikawa Y; Tanaka C; Ebisu T
Acta Neurochir Suppl (Wien); 1988; 43():140-4. PubMed ID: 3213641
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
[TBL] [Abstract][Full Text] [Related]
13. Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4.
Aleksandrzak K; McGown AT; Hadfield JA
Anticancer Drugs; 1998 Jul; 9(6):545-50. PubMed ID: 9877243
[TBL] [Abstract][Full Text] [Related]
14. Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology.
Yin T; Liu Y; Peeters R; Feng Y; Yu J; Himmelreich U; Oyen R; Ni Y
Br J Cancer; 2017 Nov; 117(10):1529-1536. PubMed ID: 28910821
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 31P MRS and 1H MRI at 1.5 and 2.0 T.
Boska MD; Hubesch B; Meyerhoff DJ; Twieg DB; Karczmar GS; Matson GB; Weiner MW
Magn Reson Med; 1990 Feb; 13(2):228-38. PubMed ID: 2314213
[TBL] [Abstract][Full Text] [Related]
16. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.
Muruganandham M; Alfieri AA; Matei C; Chen Y; Sukenick G; Schemainda I; Hasmann M; Saltz LB; Koutcher JA
Clin Cancer Res; 2005 May; 11(9):3503-13. PubMed ID: 15867253
[TBL] [Abstract][Full Text] [Related]
17. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
Kirwan IG; Loadman PM; Swaine DJ; Anthoney DA; Pettit GR; Lippert JW; Shnyder SD; Cooper PA; Bibby MC
Clin Cancer Res; 2004 Feb; 10(4):1446-53. PubMed ID: 14977848
[TBL] [Abstract][Full Text] [Related]
18. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.
Li L; Rojiani A; Siemann DW
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):899-903. PubMed ID: 9845118
[TBL] [Abstract][Full Text] [Related]
19. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI.
Zhao D; Jiang L; Hahn EW; Mason RP
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):872-80. PubMed ID: 15936572
[TBL] [Abstract][Full Text] [Related]
20. Modulation of murine radiation-induced fibrosarcoma-1 tumor metabolism and blood flow in situ via glucose and mannitol administration monitored by 31P and 2H nuclear magnetic resonance spectroscopy.
Hwang YC; Kim SG; Evelhoch JL; Seyedsadr M; Ackerman JJ
Cancer Res; 1991 Jun; 51(12):3108-18. PubMed ID: 1904001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
